Semaglutide: A New Look at Obesity, Diabetes, Fatty Liver and the Future of Treatment

About this book

The rise of obesity and metabolic disease across societies has made the case for novel, evidence-based treatment approaches unavoidable. Medications targeting the GLP-1 hormonal pathway are among the most significant therapeutic advances of recent years, enabling more effective weight management and improvement in metabolic disorders — and shifting the framing of obesity from a behavioural problem to a chronic, treatable disease.

The book traces semaglutide's regulatory history, from its approval for long-term weight management in adults with obesity, through the formulations approved for type 2 diabetes, to the oral formulation and, most recently, the approval of injectable semaglutide for adults with metabolic steatohepatitis (MASH) accompanied by moderate to advanced fibrosis.

That last development is examined in detail. Evidence discussed in the book indicates that semaglutide's effect on fatty liver disease extends beyond weight loss: sustained weight reduction, improved insulin resistance, and reduced systemic inflammation each lower liver fat, while phase 3 trial data suggest effects on the structure of the disease itself — resolution of hepatic inflammation and, in a subset of patients, improvement in fibrosis.

The book also covers the localisation of these therapies, including Soyma, an Iranian semaglutide formulation developed to widen access and reduce dependence on imported products. Throughout, the aim is to bridge specialised knowledge and practical understanding so that readers can make informed, realistic decisions.

What the book covers